Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New enteropeptidase inhibitors identified at SCOHIA PHARMA

March 17, 2020

Japanese approval for new Ozempic SD subcutaneous injection formulation

March 16, 2020

NPSR1 as a novel nonhormonal target in endometriosis

March 16, 2020

Researchers present phase II data for tafoxiparin in women in labor

March 16, 2020

Novo Nordisk initiates phase I study of NNC0472-0147 for type 2 diabetes

March 11, 2020

KeyBioscience discloses new compounds for diabetes

March 11, 2020

Dare presents data in support of sildenafil cream for female sexual arousal disorder

March 10, 2020

FDA approves Isturisa for Cushing's disease

March 9, 2020

Matinas BioPharma initiates ENHANCE-IT study of MAT-9001

March 6, 2020

FGL1 as a novel therapeutic target in obesity

March 5, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...